Hey there,
Assuming you mean NewPath Health? I'll be honest, the entire small cap healthcare space has been decimated. You look at JNH, DOC, NPTH, etc - they all are down significantly from multi-year highs. I think that in most cases, the drops are a little overdone but patience will be needed for these company to recover. IN NewPath's case, at least they continue to grow on a revenue basis but the biggest drawback is that they are no profitable even though they are generating positive EBITDA. The company did some restructuring in Q3 which should help with operations as well.
TBH - if you can afford to wait it out - it may be worth it as there may be some value here. The company only has a market cap of $5M right now which does seem cheap. The company's new CEO seems to be taking the right steps and if you haven't already - I'd have a read of their recent letter to shareholders:
https://finance.yahoo.com/news/neupath-ceo-letter-shareholders-123000008.html?.tsrc=rss
You do have to take the letter with a certain skepticism but what he is saying does make sense and does seem logical. The company still needs to prove itself and has a long way to go, especially in this environment that has not yet fully warmed back up to small caps. If it were me, I'd likely wait it out a few quarters with the new CEO at the helm to see how the company executes. All in all however, it likely won't be a quick turnaround.
Mat